Skip to main content
Premium Trial:

Request an Annual Quote

Varian, Agilent Extend Date of Expected Merger Completion

NEW YORK (GenomeWeb News) – Varian has provided Agilent Technologies with a written notice that it has extended the "end date" for their merger agreement 90 days to April 26, 2010.

Varian disclosed the extension in a US Securities and Exchange Commission filing last week. It said that the deal is still subject to regulatory approvals and other closing conditions.

Agilent signed a definitive agreement to acquire Varian for $52 per share, or a total of around $1.5 billion, back in July.

The merger was cleared by European regulatory authorities two weeks ago, but with conditions, including the sale of product lines accounting for revenues of "under $100 million" in 2009. The firms were not more specific regarding the revenue figures.

The product lines to be sold include Varian's laboratory gas chromatography business, its triple quadrupole gas chromatography-mass spectrometry business, and its inductively coupled plasma-mass spectrometry business. In addition, Agilent has committed to sell its micro gas chromatography business.

The partners have said that they do not expect US regulators to seek any additional remedies beyond those stipulated in Europe. However, the US Federal Trade Commission has yet to clear the deal.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.